FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks

"The death of almost one million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,” said FDA Commissioner Marty Makary, M.D., M.P.H. “This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and post-market monitoring so that nothing like this ever happens again.”

The post FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks appeared first on Healthcare Communications Network.